Both drugs have biochemically defined targets, lovastatin for HMGCR and troglitazone for PPARγ, and exhibit anti-tumor effects when combined in a sub-lethal concentration (Figure 1 and Figure 4). The gene discussed is HMGCR; the disease is neoplasm.